

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/178175 A1

(51) International Patent Classification:

A61K 9/08 (2006.01) *A61P 31/00* (2006.01)
A61P 37/06 (2006.01) *A61P 37/02* (2006.01)
C07K 14/81 (2006.01) *A61K 47/18* (2017.01)
A61K 38/00 (2006.01) *A61K 47/36* (2006.01)

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(21) International Application Number:

PCT/US2022/016864

(22) International Filing Date:

17 February 2022 (17.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2102258.7 17 February 2021 (17.02.2021) GB

(71) Applicant: **ARECOR LIMITED** [GB/GB]; Chesterford
Research Park, Little Chesterford, Saffron Walden CB10
1XL (GB).

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(72) Inventor; and

(71) Applicant: **AMANULLAH, Ashraf** [US/US]; c/o Inhibrx,
Inc., 11025 N. Torrey Pines Road, Suite 200, La Jolla, Cal-
ifornia 92037 (US).

(72) Inventors: **JEZEK, Jan**; c/o Arecor Limited, Chester-
ford Research Park, Little Chesterford, Saffron Walden
CB10 1XL (GB). **GERRING, David**; c/o Arecor Lim-
ited, Chesterford Research Park, Little Chesterford, Saf-
fron Walden CB10 1XL (GB). **CREMIN, Joshua**; c/o
Arecor Limited, Chesterford Research Park, Little Chester-
ford, Saffron Walden CB10 1XL (GB). **PINTO, Jorge**; c/o
Arecor Limited, Chesterford Research Park, Little Chester-
ford, Saffron Walden CB10 1XL (GB). **LOBO, Brian**; c/
o Inhibrx, Inc., 11025 N. Torrey Pines Road, Suite 200, La
Jolla, California 92037 (US). **HAYES, Bradley**; c/o Inhi-
brx, Inc., 11025 N. Torrey Pines Road, Suite 200, La Jolla,
California 92037 (US).

(74) Agent: **KOZAKIEWICZ, Cynthia A.** et al.; Cooley LLP,
1299 Pennsylvania Ave., Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

(54) Title: AQUEOUS SOLUTION COMPOSITIONS FOR INCREASING STABILITY OF ENGINEERED DIMERIC PROTEINS

(57) Abstract: The present application relates to aqueous solution compositions of engineered dimeric proteins comprising monomers that comprise at least one human serpin polypeptide operably linked to a human immunoglobulin Fc polypeptide or a polypeptide that is derived from an immunoglobulin Fc polypeptide, at low buffer concentrations and low ionic strength and containing a neutral amino acid. The aqueous solution compositions increase the stability of the an Fc domain in aqueous solution compositions, and in particular increase the stability of an engineered dimeric protein.

WO 2022/178175 A1